Table 3.
Local and systemic side effects of AstraZeneca COVID-19 vaccine among European healthcare workers, February–March 2021.
| Variable | Outcome | <35 Years-Old | 35–49 Years-Old | >49 Years-Old | Total | Sig. 1 |
|---|---|---|---|---|---|---|
| Local SEs | Injection Site Pain | 42 (82.4%) | 16 (69.6%) | 9 (50%) | 67 (72.8%) | 0.028 |
| Injection Site Swelling | 8 (15.7%) | 1 (4.3%) | 1 (5.6%) | 10 (10.9%) | 0.343 | |
| Injection Site Redness | 5 (9.7%) | 4 (17.4%) | 1 (5.6%) | 10 (10.9%) | 0.539 | |
| Total | 42 (82.4%) | 17 (73.9%) | 9 (50%) | 68 (73.9%) | 0.035 | |
| Systemic SEs | Fatigue | 46 (90.2%) | 13 (56.5%) | 9 (50%) | 68 (73.9%) | <0.001 |
| Headache | 18 (35.3%) | 8 (34.8%) | 1 (5.6%) | 27 (29.3%) | 0.040 | |
| Nausea | 28 (54.9%) | 8 (34.8%) | 6 (33.3%) | 42 (45.7%) | 0.138 | |
| Feeling Unwell | 26 (51%) | 10 (43.5%) | 7 (38.9%) | 43 (46.7%) | 0.634 | |
| Muscle Pain | 33 (64.7%) | 12 (52.2%) | 6 (33.3%) | 51 (55.4%) | 0.066 | |
| Joint Pain | 24 (47.1%) | 8 (34.8%) | 6 (33.3%) | 38 (41.3%) | 0.456 | |
| Fever | 8 (15.7%) | 5 (21.7%) | 1 (5.6%) | 14 (15.2%) | 0.353 | |
| Chills | 31 (60.8%) | 9 (39.1%) | 5 (27.8%) | 45 (48.9%) | 0.031 | |
| Lymphadenopathy | 4 (7.8%) | 1 (4.3%) | 0 (0%) | 5 (5.4%) | 0.707 | |
| Total | 49 (96.1%) | 17 (73.9%) | 13 (72.2%) | 79 (85.9%) | 0.003 | |
|
SEs
Duration |
1 day | 27 (54%) | 10 (47.6%) | 12 (75%) | 49 (56.3%) | 0.136 |
| 3 days | 20 (40%) | 7 (33.3%) | 4 (25%) | 31 (35.6%) | ||
| 5 days | 2 (4%) | 2 (9.5%) | 0 (0%) | 4 (4.6%) | ||
| 1 week | 1 (2%) | 2 (9.5%) | 0 (0%) | 3 (3.4%) | ||
| Total | 50 (98%) | 21 (91.3%) | 16 (88.9%) | 87 (94.6%) | 0.141 | |
| Total SEs | (0–12) | 5.35 ± 2.40 | 4.13 ± 2.94 | 2.89 ± 2.45 | 4.57 ± 2.71 | 0.001 |
1 Chi-squared test, Fisher’s exact test and Kruskal–Wallis test were used with a significance level of <0.05.